Breast Cancer | Clinical

November 26, 2021

The TROPION-Breast01 study aims to enroll 700 patients to determine the safety and efficacy of datopotamab deruxtecan in patients with HR-positive, HER2-negative breast cancer.

November 20, 2021

Evanthia Roussos Torres, MD, PhD, discusses the phase 1 study of the efficacy of entinostat administered in combination with nivolumab and ipilimumab for the treatment of locally advanced, metastatic, unresectable, or HER2-negative breast cancer.

November 19, 2021

A novel liquid biopsy for the detection of early-stage breast cancer has been granted a breakthrough device designation from the FDA.

November 19, 2021

The phase 2b AIPAC study, Eftilagimod alpha was found to improve overall survival in metastatic breast cancer along with a tolerable safety profile.

November 16, 2021

Elisa Agostinetto, MD, discusses the next steps in the research into the accuracy of PREDICT+ to predict survival in HER2-positive breast cancer.

November 15, 2021

Looking at 2 years' worth of data for patients with ERBB2-negative breast cancer, a study showed that the anti-inflammatory agent celecoxib had no disease free survival benefit.

November 12, 2021

Joseph A. Sparano, MD, who recently gave a talk during the 19th Annual School of Breast Oncology, discusses prolonging responses to therapy in patients with advanced breast cancer.

November 08, 2021

After showing significant improvement in survival, a breakthrough therapy designation application for leronlimab has been submitted to the FDA.

October 28, 2021

Florida Cancer Specialists & Research Institute, in collaboration with AdventHealth Heart of Florida and Central Florida Cancer Institute, has received a 3-year accreditation from the National Accreditation Program for Breast Centers.

October 27, 2021

After discovering the potential of a prophylactic breast cancer vaccine, Cleveland Clinic will be the site of a phase 1 clinical trial to test its safety.